Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Short-term treatment of hypertension when oral therapy is not feasible or desirable
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion of 5 mg/hour initially, titrated by 2.5 mg/hour every 15 minutes up to 15 mg/hour for acute hypertension. Typical infusion rate: 5-15 mg/hour.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is approximately 2-4 hours in healthy adults; prolonged to about 7 hours in cirrhosis or hepatic impairment.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Hepatic via CYP3A4 and CYP2C8
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 35% of metabolites.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
>95% bound primarily to albumin.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.6-1.5 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100%; Oral: approximately 35% due to extensive first-pass metabolism.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No dosage adjustment required for mild to moderate renal impairment (Cr Cl >30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific dose reduction recommended but monitor closely.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
In Child-Pugh Class A or B, reduce initial infusion rate to 2.5 mg/hour and titrate slowly. Avoid use in Child-Pugh Class C due to significant accumulation.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
For children ≥2 years: Initial intravenous infusion of 0.5-1 mcg/kg/minute, titrate by 0.5 mcg/kg/minute every 5-15 minutes to desired effect. Maximum: 5 mcg/kg/minute.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Initiate at lower end of dosing range (2.5-5 mg/hour intravenous infusion) and titrate slowly due to increased sensitivity and potential for hypotension.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA boxed warning.
None.
Use caution in patients with heart failure, hepatic impairment, renal impairment, or acute cardiovascular disease. May cause hypotension, tachycardia, and peripheral edema. Monitor blood pressure and heart rate during infusion. Avoid abrupt discontinuation. Use with caution in patients with coronary artery disease due to possible reflex tachycardia.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to nicardipine or any component,Advanced aortic stenosis,Patients with known hypersensitivity to dihydropyridine calcium channel blockers
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Grapefruit products (fruit and juice) should be avoided as they inhibit CYP3A4 metabolism of nicardipine, increasing its serum concentration and risk of hypotension and other adverse effects. No other significant food interactions known.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
NICARDIPINE (CARDENE) - Teratogenic risk profile: First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: No increased risk of major malformations reported; potential for maternal hypotension and fetal hypoxia with high doses. Avoid use in pregnancy-induced hypertension unless benefit outweighs risk.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
NICARDIPINE (CARDENE) - Lactation summary: Excreted into breast milk in low concentrations (M/P ratio approximately 0.7); no adverse effects reported in infants. Use with caution, especially in preterm infants due to immature hepatic metabolism.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
NICARDIPINE (CARDENE) - Dosing adjustments in pregnancy: Pregnancy increases volume of distribution and clearance; dose requirements may be higher. Start at low end of dosing range and titrate to effect, monitoring for hypotension. Intravenous infusion: 5 mg/hour initially, increased by 2.5 mg/hour every 5-15 minutes to a maximum of 15 mg/hour.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Cardene (nicardipine) IV is a dihydropyridine calcium channel blocker used for short-term treatment of hypertension when oral therapy is not feasible. It has rapid onset and is titratable. Monitor for hypotension, reflex tachycardia, and peripheral edema. Use with caution in patients with aortic stenosis, coronary artery disease, or heart failure. It is compatible with 0.83% sodium chloride; avoid adding other drugs. Protect from light. Titrate based on blood pressure response. Hypotension may be profound in volume-depleted patients.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously to lower your blood pressure. Report any dizziness, lightheadedness, or fainting immediately.,You may experience swelling in your legs or ankles. Notify your healthcare provider if this becomes bothersome.,Avoid sudden changes in position (e.g., standing up quickly) to prevent falls.,Do not consume grapefruit or grapefruit juice while on this medication, as it can increase the drug's effects and risk of side effects.,Inform your doctor if you have a history of liver or kidney disease, heart problems, or if you are pregnant or breastfeeding.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is a Electrolyte that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is: Intravenous infusion of 5 mg/hour initially, titrated by 2.5 mg/hour every 15 minutes up to 15 mg/hour for acute hypertension. Typical infusion rate: 5-15 mg/hour.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category A/B. NICARDIPINE (CARDENE) - Teratogenic risk profile: First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimeste. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.